Boehringer Hopes To Tap AbbVie's ''Humira Magic'' In Immunology Pact
This article was originally published in Scrip
Boehringer Ingelheim and AbbVie Inc. have launched a global collaboration to develop two of the German group's most advanced biologic compounds in immunology, a therapy field where the US-based group has acquired extensive insight from its TNF inhibitor Humira (adalimumab).
You may also be interested in...
A Virtuous Cycle: What The Immuno-Oncology Revolution Means For Other Disease Areas
Execs from Merck, Pfizer, Bristol, Abbvie and smaller biopharmas weigh in on how developments in cancer research may benefit other disease areas, especially autoimmune and neurological conditions.
Q&A: AbbVie VP Lin On Filling Humira's Big Shoes In Immunology
AbbVie's Shao-Lee Lin talks about drug candidates that the company hopes will extend its legacy in immunology, which is built on the foundation of the world's top-selling biopharma product Humira.
ACR Roundup: JAK Safety Shown Across Multiple Trials
Low cardiovascular risk was shown in trials presented at the ACR/ARHP annual meeting for Pfizer's, Lilly's and AbbVie's JAK inhibitors in rheumatoid arthritis; AbbVie's Phase II risankizumab results in PsA, biosimilar doubts and more from ACR.